A Phase II Study to Evaluate the Surgical Conversion Rate in Patients Receiving FOLFOXIRI +/- Cetuximab for Unresectable Wild-Type KRAS/NRAS Colorectal Cancer With Metastases Confined to the Liver
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2016
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Acronyms FOCULM
- 19 Sep 2016 Planned End Date changed from 1 Feb 2017 to 1 Feb 2020.
- 19 Sep 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2018.
- 19 Mar 2014 New trial record